TNDM Stock Forecast & Price Target

Tandem Diabetes Care has demonstrated resilience and continued growth, with projected revenues for 2026 increasing slightly to $1.111 million and for 2027 to $1.229 million. The firm is regaining traction in new patient starts in the US, with estimated growth around 4% year-over-year driven by improved access via pharmacy channels and the successful adoption of its Mobi pump. Additionally, the company reported strong performance metrics, including a revenue beat of approximately $14 million, primarily attributed to outperformance in the US market and pricing advancements from increased pharmacy penetration.

Tandem Diabetes Care has faced considerable operating losses since its inception and has not demonstrated the ability to achieve sustained profitability, casting doubt on its financial stability. The company anticipates flat to slightly declining new patient starts in the U.S., with an expected decrease of 3% in 2025, and potential risks include increased competition and challenges in securing favorable pharmacy channel contracts. Despite a slight increase in US pump shipments, overall growth remains stagnant, evidenced by a year-over-year decline of 4%, alongside lower growth margins and EBITDA figures compared to peers.